fashion -WSS

fashion

author：entertainment 2025-10-01 00:16:42 - browse：978

Adobe

WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a move by Congress to add the company to a blacklist meant to prevent certain biotech firms from doing business in the United States.

Legislation proposing that blacklist, known as the BIOSECURE Act, was passed in a 40-1 bipartisan vote on Wednesday by the House Oversight and Accountability Committee. That’s an important development because until now, the House Select Committee on the Chinese Communist Party had handled the bill in the House. That panel is an ad-hoc committee created to build bipartisan consensus on China policies, but it does not have the authority to pass legislation. A Senate committee also passed the BIOSECURE Act nearly unanimously earlier this year.

With the bill out of the Oversight Committee, the goal is for the House to pass it before the July 4 recess. That would set the legislation up to be included in a year-end must-pass legislative package, possibly the National Defense Authorization Act, which Congress has passed every year for decades.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Donor acceptance rates hint at racial, gender bias in heart transplants: study

hotspot

WSS

Abortion pill Supreme Court ruling could impact entire drug industry

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Patient advocates debate FDA's accelerated approval process

UnitedHealth financials solid despite Change Healthcare cyberattack

Bird flu in milk supply is likely coming from asymptomatic cows

Orangutan used medicinal plant to treat wound, first time ever seen

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Merck, Vertex, and Viking updates

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Merck, Vertex, and Viking updates

Virginia high school admissions case could be legal follow

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Trump demands the U.S. pay no more for drugs than other countries … again

Supreme Court mifepristone arguments center on docs' right to sue

Malaria cases in Florida and Texas: Here’s what you need to know

Dogs on Prozac: What pet anti

explore

Washington mulls new rules to avert another Change Healthcare

Melinda French Gates resigns from Gates Foundation

FDA's naming rule on biosimilars has undermined competition

MultiPlan and major insurers sued for alleged medical price

Decaf coffee targeted by food safety group under obscure FDA rule

Merck drug for rare lung condition set for approval in U.S.

knowledge

focus

hotspot

explore